Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Liabilities (2023 - 2025)

CG Oncology filings provide 3 years of Total Liabilities readings, the most recent being $39.0 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 82.03% to $39.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $39.0 million, a 82.03% increase, with the full-year FY2025 number at $39.0 million, up 82.03% from a year prior.
  • Total Liabilities hit $39.0 million in Q4 2025 for CG Oncology, down from $42.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $107.6 million in Q3 2023 to a low of $10.2 million in Q1 2024.
  • Median Total Liabilities over the past 3 years was $27.3 million (2025), compared with a mean of $41.7 million.
  • Biggest five-year swings in Total Liabilities: plummeted 88.19% in 2024 and later soared 169.22% in 2025.
  • CG Oncology's Total Liabilities stood at $14.5 million in 2023, then skyrocketed by 47.61% to $21.4 million in 2024, then surged by 82.03% to $39.0 million in 2025.
  • The last three reported values for Total Liabilities were $39.0 million (Q4 2025), $42.3 million (Q3 2025), and $31.1 million (Q2 2025) per Business Quant data.